This casebook is uniquely intended to address the niche created by the intersection of business strategy with biotechnology and pharmaceuticals. In addition, it highlights some recent trends (both opportunities and threats) in the field if life sciences. As authors of business strategy cases may attest, the difficulty in obtaining current information may cause lags in subject area coverage. Indeed, some of the cases in this book also underscore the surprisingly vast spaces in the life sciences sector, in which opportunities may abound. This casebook also features several advancements in adjacent industries that have and will continue to have implications for biopharma firm strategies. In particular, advancements in the design of experiments and statistics, chemistry, artificial intelligence, quantum computing, finance, and microfluidics, to name but a few, are featured. This casebook is also designed to showcase novel applications of or insights into strategic management theory. Issues in ecosystem leadership, opportunity costs and bioethics, dominant design/industry life cycle, intangible sources of sustained advantage, leveraging public projects for private gain, corporate identity, and postmodern perspectives on the resource-based view are addressed. Finally, this case book is also written in a format which is compatible with most standard textbook treatments of strategic management.
Auflage
Sprache
Verlagsort
Newcastle upon Tyne
Großbritannien
Zielgruppe
Editions-Typ
Produkt-Hinweis
Maße
Höhe: 212 mm
Breite: 148 mm
ISBN-13
978-1-0364-0729-2 (9781036407292)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Klassifikation
Martin Monroe has been fascinated by the intersection of biotechnology and strategic management for many years. He has relevant advanced degrees in both management (PhD, MBA) and technology (MS Biotechnology, BS Chemical Engineering). In academia, he has taught over 2,500 MBA and Undergraduate students at four different universities, published original articles in academic journals, and authored original strategy cases. In industry, he also has been a venture capitalist in the life sciences sector, founded and led an early-stage genetic engineering/bio-based chemicals firm, and served as a corporate strategy consultant for a Fortune 50 firm.